Presentation of tumor antigens

Hart, D. N., Schultze, J. L. and Stewart, A. K. (1999) Presentation of tumor antigens. Seminars in Hematology, 36 1 Supp. 3: 21-25.

Author Hart, D. N.
Schultze, J. L.
Stewart, A. K.
Title Presentation of tumor antigens
Journal name Seminars in Hematology   Check publisher's open access policy
ISSN 0037-1963
Publication date 1999-01-01
Sub-type Article (original research)
Volume 36
Issue 1 Supp. 3
Start page 21
End page 25
Total pages 5
Place of publication Philadelphia, PA
Publisher W B Saunders
Language eng
Subject C1
730108 Cancer and related disorders
110709 Tumour Immunology
Formatted abstract
Dendritic cells, with their extraordinary capacity for initiating primary and secondary T-lymphocyte responses, may be pivotal in the development of immunotherapeutic strategies for multiple myeloma.
Although host lymphocytes are able to recognize tumor-associated antigens (TAAs), many tumors are able to avoid dendritic cell-mediated immune surveillance. One reason may be that the tumor environment inhibits the maturation and activation of dendritic cells.
A recently developed strategy to use dendritic cells in immunotherapy involves removing them from the tumor, pulsing them in vitro with antigen, and reinfusing them into the patient to generate responding T cells in vivo. Methods for reliably obtaining dendritic cells for therapeutic use are currently being investigated. Among other efforts to induce T-cell-mediated immunity against cancer, the presentation of tumor antigens by the tumor cells themselves is being investigated. Issues to be resolved include defects of antigen presentation by tumor cells and whether all cells present the same set of peptides.
Moreover, as long as all the tumor antigens have not been identified, the tumor cell itself remains the primary source of unknown antigens and, therefore, is a worthwhile subject for study. Phase I trials of immunotherapy using adenovirus-infected autologous plasma cells have recently been undertaken. The adenoviral vectors carry genes with therapeutic potential, including interleukin-2 (IL-2), interleukin-12, and B7-1.
Initial results showed that the vector can be readily detected in tumor cells at 13 days postinjection, and IL-2 expression was evident at 7 days. The chief side effect reported was inflammation.
Keyword Hematology
Dendritic Cells
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 11 Jun 2008, 01:52:27 EST